Skip to main content
Quest Diagnostics
Talk to an expert
Call
Menu

Primary care is the first line of defense for patients experiencing symptoms of autoimmune disorders

You know firsthand that recognizing autoimmune disease can be challenging due to vague, variable, and overlapping symptoms. That makes it even more important for you to get comprehensive autoimmune insights for your patients sooner, so you can make sure the next step taken on their healthcare journey is in the right direction. 

You are critical to helping improve patient outcomes

To support faster autoimmune diagnoses with fewer steps, we’ve developed a tool providing guidance on the clinical significance of results for ANA and 25 disease-specific biomarkers

Get the resource

A negative ANA result may not tell the whole story

ANAlyzeRTM  supports more comprehensive autoimmune screening by combining ANA testing by IFA with immunoassays for additional AI disease-associated biomarkers, performed together from a single sample. Real-world ANAlyzeR data from January 1 to December 31, 2024, shows that additional AI disease-associated biomarkers are present even when ANA by IFA is negative.1
ANAlyzeR Data Analysis review guide
ANAlyzeR_Data_Analysis_Review

It’s crucial to get earlier insights through comprehensive autoimmune screening

 Delayed autoimmune diagnosis and treatment can result in permanent joint and organ damage and lower the chance of remission.2 It’s more important than ever for PCPs to use comprehensive autoimmune screening solutions due to

Non-specificity with ANA screening 

Antinuclear antibody (ANA) screening alone is not disease-specific, meaning it requires more follow-up visits and testing.

Diagnosis of Autoimmune disease can be a lengthy process

  • On average, autoimmune patients see multiple doctors over a 4-year period, before a diagnosis is made3 
  • Studies show patients often experience extended waits for a specialist evaluation4,5

Recent increase of at-risk populations 

>100 million confirmed US COVID-19 cases,6 with data suggesting this population has a significantly higher risk of autoimmune disease7

 

 

Autoimmune symptoms may be complex, but getting answers doesn’t have to be

1 test code. 1 blood draw. 1 confident referral. More insights. Learn how our comprehensive screening panels deliver ANA results plus disease-specific insights you can translate into a more qualified referral and a faster path to diagnosis. 
Download the free guide
AI interpretation guide thumbnail

New Insights on Demand Webinar: Autoimmune disease and cardiometabolic risk

This presentation will

  • Explore the ever-evolving role of primary care physicians in diagnosing autoimmune disease
  • Build confidence in results interpretation for comprehensive autoimmune testing with the ANAlyzeR™ panel
  • Review the necessity of monitoring and managing comorbidity risk between autoimmune disease and cardiometabolic disease

Help your patients get the care they need sooner

Reliable results

  • Greater sensitivity with ANA gold-standard indirect fluorescent antibody (IFA) methodology
  • Improved consistency through automation

Accessible testing

Actionable insights

  • Identifies multiple ANA patterns and disease-specific autoantibodies
  • Expansive approach supports more informed referrals

Easy, simplified experience

  • One blood draw reduces need for follow-up visits and tests
  • Access to clinical consults and account support

ANAlyzeR - The analytic approach

ANAlyzeRTM ANA, IFA, with Reflex Titer/Pattern, Systemic Autoimmune Panel 1

Fixed panel of 25 analytes that gives a full-picture view (whether ANA is positive or negative) to support differential diagnosis, especially for patients with more than 1 autoimmune condition
View test details
Hereditary oncology spotlight

Cascade - The reflexive approach

ANA, IFA, Cascade and Rheumatoid Arthritis Panel 2, with Reflexes

Automatic reflex panel that tests for the 8 most common autoimmune diseases using a tiered cascade approach when ANA results are positive
View test details
Provider walking a patient through results

Your Quest expert is only a phone call away

Let’s discuss some of the key challenges your lab is facing and how we can work together to find the right solution for your diagnostic needs.

684

* indicates required

 

 

1. Data on file. Quest Diagnostics; 2026.

2. Niemantsverdriet E, Dougados M, Combe B, van der Helm-van Mil AHM. Referring early arthritis patients within 6 weeks versus 12 weeks after symptoms onset; an observational cohort study. Lancet Rheumatol. 2020;2(6):e332-e338. doi:10.1016/S2665- 9913(20)30061-8

3. Autoimmune Association. Tips for getting a diagnosis of an autoimmune disease. Accessed February 24, 2026. https://autoimmune.org/resource-center/diagnosis-tips/

4.  Liu X, Patel AB, Seidel JE, et al. Traveling towards timeliness: the association between geographic access and wait times for rheumatology consultation in a centralized referral system. Healthcare (Basel). 2025;13(19):2533. doi:10.3390/healthcare13192533  

5. Mechleb K, Hmamouchi I, Abdulateef N, et al. Exploring diagnostic timelines: a cross-sectional study of referral and diagnostic delays of patients with chronic inflammatory rheumatic diseases. Arab J Rheumatol. 2025;3:5-13. doi:10.4103/ajr.ajr_17_24 

6. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization. Updated July 12, 2023. Accessed July 18, 2023. https://covid19.who.int/region/amro /country/us

7. Chang R, Yen-Ting Chen T, Wang SI, et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. eClinicalMedicine. 2023;56:101783. doi:10.1016/j.eclinm.2022.101783

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.